Gynaecological Oncology, UCL EGA Institute for Women's Health, London, UK.
Cancer Prev Res (Phila). 2011 Mar;4(3):299-302. doi: 10.1158/1940-6207.CAPR-11-0048.
This perspective discusses reports by Cramer and colleagues (beginning on page 365 in this issue of the journal) and Zhu and colleagues (beginning on page 375), which provide the first systematic and reliable comparison of a large number of candidate biomarkers for the early detection of ovarian cancer in a sample set well-suited for this purpose. This research has important implications for the future design of cancer biomarker studies.
这篇观点文章讨论了 Cramer 及其同事（本期杂志第 365 页开始）和 Zhu 及其同事（第 375 页开始）的报告，这些报告首次对大量候选生物标志物进行了系统、可靠的比较，以用于早期检测适合此类目的的卵巢癌样本。这项研究对未来癌症生物标志物研究的设计具有重要意义。
